Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY24 results · Jul–Sep 2023
Torrent Pharmaceuticals reported revenue from operations of ₹2,660.00 crore (up 16.1% from Q2 FY23) and net profit of ₹386.00 crore (up 23.7% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,660.00 | 2,291.00 | +16.1% | 2,591.00 | +2.7% |
| Other income | 26.00 | 16.00 | +62.5% | 34.00 | −23.5% |
| Total income | 2,686.00 | 2,307.00 | +16.4% | 2,625.00 | +2.3% |
| Profit before tax | 559.00 | 463.00 | +20.7% | 531.00 | +5.3% |
| Net profit for the period | 386.00 | 312.00 | +23.7% | 378.00 | +2.1% |
| Attributable to shareholders of the company | 363.00 | 312.00 | +16.3% | 378.00 | −4.0% |
| EPS, basic (₹) | 11.39 | 9.22 | +23.5% | 11.18 | +1.9% |
| Net margin (%) | 14.5 | 13.6 | 14.6 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,146.00 | 1,928.00 | +11.3% | 2,121.00 | +1.2% |
| Other income | 15.00 | 11.00 | +36.4% | 11.00 | +36.4% |
| Total income | 2,161.00 | 1,939.00 | +11.4% | 2,132.00 | +1.4% |
| Profit before tax | 482.00 | 413.00 | +16.7% | 475.00 | +1.5% |
| Net profit for the period | 327.00 | 272.00 | +20.2% | 323.00 | +1.2% |
| EPS, basic (₹) | 9.65 | 8.02 | +20.3% | 9.55 | +1.0% |
| Net margin (%) | 15.2 | 14.1 | 15.2 |
Consolidated
- Filed with BSE
- 25 Oct 2023, 13:18 IST
- Board meeting
- 23 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Oct 2023, 13:18 IST
- Board meeting
- 23 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Audited
- Source
- XBRL filing on BSE